Pfizer has announced the results of its Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) interim analysis, revealing that its antiviral pill Paxlovid reduced the risk of hospitalization and death by 89-percent in high-risk adults who had COVID-19. The protective effect was compared to a group of patients who received a placebo drug, paving the way …
Pfizer's "overwhelming" COVID-19 pill results fuel home treatment hopes
Slash Gear - 5 Nov 2021 21:51
Pfizer has announced the results of its Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) interim analysis, revealing that its antiviral pill Paxlovid reduced the risk of hospitalization and death by 89-percent in high-risk adults who had COVID-19. The protective effect was compared to a group of patients who received a placebo drug, paving the way …
Share this Article
Recommended